Elanco Animal Health (ELAN) is back in focus after the Securities and Exchange Commission approved a Plan of Distribution for the company’s US$15,000,000 Fair Fund tied to past disclosure violations.
See our latest analysis for Elanco Animal Health.
At a share price of US$25.00, Elanco Animal Health has posted a 3.78% 1 day and 8.32% 90 day share price return. Its 1 year total shareholder return of 70.77% and 3 year total shareholder return of 149% point to strong momentum building around the stock despite the overhang of past disclosure issues and ongoing insider equity grants.
If this kind of renewed interest in Elanco has you thinking about where else capital might find long term growth, it could be a good moment to scan 20 top founder-led companies
With Elanco Animal Health trading at US$25.00, alongside a 34.57% intrinsic discount estimate and a 19.43% gap to analyst targets, is the current price still leaving upside on the table or already reflecting future growth?
Most Popular Narrative: 16.1% Undervalued
Against Elanco Animal Health's last close of $25.00, the most followed narrative anchors fair value at $29.79, framing the stock as trading at a meaningful discount under that framework.
Operational focus on product launches and portfolio optimization has started to move the needle on debt and profitability. By trimming non core businesses and channeling resources into higher margin areas, Elanco is targeting a healthier net margin profile that could support stronger earnings quality over time.
Want to see what sits underneath that $29.79 fair value? The narrative leans heavily on a blend of steady revenue growth, rising margins, and a future earnings multiple that assumes real progress against those goals. Curious how those moving parts combine into a single valuation story? The full breakdown lays out the exact pathway that needs to play out for Elanco Animal Health to close that gap.
Result: Fair Value of $29.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Elanco Animal Health story could be tested if foreign exchange pressures hit reported results or if new launches like Zenrelia and Credelio Quattro experience slower uptake.
Find out about the key risks to this Elanco Animal Health narrative.
Next Steps
If the mix of risks and optimism around Elanco Animal Health leaves you undecided, take a closer look at the details now and shape your own view by weighing the 3 key rewards.
Looking for more investment ideas beyond Elanco Animal Health?
If Elanco Animal Health has sharpened your focus on quality, do not stop here. Widen your opportunity set with a few targeted stock ideas screened on fundamentals.
- Target income potential with companies that offer higher yields and resilient payouts by reviewing our list of 7 dividend fortresses.
- Hunt for mispriced opportunities where solid businesses trade below their estimated worth by scanning 44 high quality undervalued stocks.
- Prioritise resilience and capital protection by focusing on companies highlighted in our 74 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com